Hamilton P, et al. - A decision-analytic model was developed by researchers to estimate the cost-effectiveness of rituximab vs the modified Ponticelli regimen (mPR) from the perspective of the National Health Service in the UK over a 1 year, 5 year and lifetime horizon, given cost of rituximab treatment limits its widespread use, especially in resource-limited healthcare systems. Rituximab therapy was shown to dominate mPR at 1-year post-treatment but was cheaper than the Ponticelli regimen at 5 years post-treatment, at a loss of 0.014 quality-adjusted life years (QALYs) with an incremental cost-effectiveness ratio (ICER) of £95 494.13. Overall, rituximab showed the potential to be a cost-effective treatment in the short and medium terms despite the high single-dose cost.